OptiBiotix Health PLC Holding(s) in Company (8694J)

TIDMOPTI

RNS Number : 8694J

OptiBiotix Health PLC

14 September 2016

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Holding in Company

The Company was informed on 13 September 2016 that Seneca Partners Limited no longer has a disclosable interest in the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                         www.optibiotix.com 
 Stephen O'Hara, Chief                 Contact via Walbrook below 
  Executive 
 
 Cairn Financial Advisers                      Tel: 020 7148 7900 
  LLP 
 Liam Murray 
 
 Hybridan LLP (Joint Broker)                   Tel: 0203 764 2341 
 Claire Louise Noyce 
 
 Peterhouse Corporate Finance                  Tel: 020 7469 0936 
  Ltd (Joint Broker) 
 Lucy Williams / Duncan 
  Vasey 
 
 Walbrook PR Ltd                            Tel: 020 7933 8780 or 
                                        optibiotix@walbrookpr.com 
 Anna Dunphy                                   Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLGGUMWBUPQGAC

(END) Dow Jones Newswires

September 14, 2016 11:38 ET (15:38 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024